Consequently, in memory clinic patients with abnormal Aβ and p-tau biomarkers it may not be clear whether AD pathology or another neurodegenerative disease is the primary etiology underlying the cognitive deficits. This evidence concerns the gene MAPT and Cognitive impairment.